Renata Cristina Tornelli Tassetano
Renata Cristina Tornelli Tassetano Treat Rev, 2005. 31(7): p. 536-45.
2. BJ, D., Renal Cell Carcinoma: Current Status and Future Prospects. Cancer Treatment Review, 2005. 31: p. 536-545.
3. Garcia, J.A. and B.I. Rini, Recent progress in the management of advanced renal cell carcinoma. CA Cancer J Clin, 2007. 57(2): p. 112-25.
4. BI, G.J.a.R., Recent Progress in the Management of Advanced Renal Cell Carcinoma. CA Cancer J Clin., 2007. 57: p. 112-125.
5. van Spronsen, D.J., P.F. Mulders, and P.H. De Mulder, Novel treatments for metastatic renal cell carcinoma. Crit Rev Oncol Hematol, 2005. 55(3): p. 177-91. 6. Tochizawa, S., et al., Antitumor effects of a combination of interferon-alpha and
sorafenib on human renal carcinoma cell lines. Biomed Res, 2008. 29(6): p. 271-8. 7. Murphy, D.A., et al., Inhibition of tumor endothelial ERK activation, angiogenesis,
and tumor growth by sorafenib (BAY43-9006). Am J Pathol, 2006. 169(5): p. 1875- 85.
8. Prenen, H., T. Gil, and A. Awada, New therapeutic developments in renal cell cancer. Crit Rev Oncol Hematol, 2009. 69(1): p. 56-63.
9. Favaro, J.P. and D.J. George, Targeted therapy in renal cell carcinoma. Expert Opin Investig Drugs, 2005. 14(10): p. 1251-8.
10. Mazzio, E.A. and K.F. Soliman, In vitro screening for the tumoricidal properties of international medicinal herbs. Phytother Res, 2009. 23(3): p. 385-98.
11. Chicca, A., et al., Cytotoxic effects of Echinacea root hexanic extracts on human cancer cell lines. J Ethnopharmacol, 2007. 110(1): p. 148-53.
12. Woelkart, K. and R. Bauer, The role of alkamides as an active principle of echinacea. Planta Med, 2007. 73(7): p. 615-23.
13. Song G, O.G.a.B.S., The activation of Akt/PKB signaling pathway and cell survival. J. Cell. Mol. Med., 2005. 9(1): p. 59-71.
14. Jiang BH and Liu LZ, PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochimica et Biophysica Acta, 2008. 1784: p. 150-158.
15. Song, G., G. Ouyang, and S. Bao, The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med, 2005. 9(1): p. 59-71.
16. Sridhar, S.S., D. Hedley, and L.L. Siu, Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther, 2005. 4(4): p. 677-85.
17. Adjei, A.A., Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst, 2001. 93(14): p. 1062-74.
18. Stavrovskaya, A.A. and T.P. Stromskaya, Transport proteins of the ABC family and multidrug resistance of tumor cells. Biochemistry (Mosc), 2008. 73(5): p. 592-604. 19. Goldie, J.H. and A.J. Coldman, A mathematic model for relating the drug sensitivity
of tumors to their spontaneous mutation rate. Cancer Treat Rep, 1979. 63(11-12): p. 1727-33.
20. Wu, C.P., A.M. Calcagno, and S.V. Ambudkar, Reversal of ABC drug transporter- mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol, 2008. 1(2): p. 93-105.
21. Ginn, P.E., Immunohistochemical detection of P-glycoprotein in formalin-fixed and paraffin-embedded normal and neoplastic canine tissues. Vet Pathol, 1996. 33(5): p. 533-41.
Renata Cristina Tornelli Tassetano 22. Bates, S.E., Drug resistance: still on the learning curve. Clin Cancer Res, 1999.
5(11): p. 3346-8.
23. Bergman, P.J., G.K. Ogilvie, and B.E. Powers, Monoclonal antibody C219 immunohistochemistry against P-glycoprotein: sequential analysis and predictive ability in dogs with lymphoma. J Vet Intern Med, 1996. 10(6): p. 354-9.
24. Ambudkar, S.V., et al., P-glycoprotein: from genomics to mechanism. Oncogene, 2003. 22(47): p. 7468-85.
25. Breier A, B.M., Sulová Z, Uhrik B., P-glycoprotein-implications of metabolism of neoplasic cells and cancer therapy. Curr Cancer Drug Tar, 2005. 5: p. 457-458. 26. H., L., ABC-transporters: implications on drug resistence from microorganisms to
human cancers. Inter J Antimicrob Agents, 2003. 22: p. 188-199.
27. Bergman, P.J., Mechanisms of anticancer drug resistance. Vet Clin North Am Small Anim Pract, 2003. 33(3): p. 651-67.
28. Loe, D.W., R.G. Deeley, and S.P. Cole, Biology of the multidrug resistance- associated protein, MRP. Eur J Cancer, 1996. 32A(6): p. 945-57.
29. Borst, P., N. Zelcer, and A. van Helvoort, ABC transporters in lipid transport. Biochim Biophys Acta, 2000. 1486(1): p. 128-44.
30. Raaijmakers, H.G., et al., Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma. Blood, 1998. 91(3): p. 1029-36. 31. Ohno, N., et al., Expression of functional lung resistance--related protein predicts
poor outcome in adult T-cell leukemia. Blood, 2001. 98(4): p. 1160-5.
32. Filipits, M., et al., Clinical relevance of the lung resistance protein in diffuse large B-cell lymphomas. Clin Cancer Res, 2000. 6(9): p. 3417-23.
33. Silva, M.T., A. do Vale, and N.M. dos Santos, Secondary necrosis in multicellular animals: an outcome of apoptosis with pathogenic implications. Apoptosis, 2008.
13(4): p. 463-82.
34. Shibuya, M., Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis. BMB Rep, 2008. 41(4): p. 278-86.
35. Homes DIR, Z.I., The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease. Genome Biology, 2005. 6: p. 209.
36. Lowry, O.H., et al., Protein measurement with the Folin phenol reagent. J Biol Chem, 1951. 193(1): p. 265-75.
37. Livak, K.J. and T.D. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 2001.
25(4): p. 402-8.
38. Anglada Curado, F.J., et al., [New epidemiologic patterns and risk factors in renal cancer]. Actas Urol Esp, 2009. 33(5): p. 459-67.
39. Wunsch-Filho, V., Insights on diagnosis, prognosis and screening of renal cell carcinoma. Sao Paulo Med J, 2002. 120(6): p. 163-4.
40. Amato, R.J., Chemotherapy for renal cell carcinoma. Semin Oncol, 2000. 27(2): p. 177-86.
41. Schieman, C., et al., Complementary and alternative medicine use among general surgery, hepatobiliary surgery and surgical oncology patients. Can J Surg, 2009.
52(5): p. 422-6.
42. Pignochino, Y., et al., Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially
Renata Cristina Tornelli Tassetano
8: p. 118.
43. Yang, F., et al., Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas. Mol Cancer Ther, 2008. 7(11): p. 3519-26.
44. Matsunaga, H., et al., Cytotoxic activity of polyacetylene compounds in Panax ginseng C. A. Meyer. Chem Pharm Bull (Tokyo), 1990. 38(12): p. 3480-2.
45. Young Sook Kim, S.H.J., Shin I! Kim and Dug Ryong Hahn, Studies on the Mechanism of Cytotoxicities of Polyacetylenes against L1210 Cell
Arch. Pharm. Res, 1989. 12(3): p. 207-213.
46. Choi, H.J., et al., Petrotetrayndiol A induces cell cycle arrest and apoptosis in SK- MEL-2 human melanoma cells through cytochrome c-mediated activation of caspases. Cancer Lett, 2006. 232(2): p. 214-25.
47. Park, C., et al., Suppression of U937 human monocytic leukemia cell growth by dideoxypetrosynol A, a polyacetylene from the sponge Petrosia sp., via induction of Cdk inhibitor p16 and down-regulation of pRB phosphorylation. Oncol Rep, 2006.
16(1): p. 171-6.
48. Kandel, E.S. and N. Hay, The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp Cell Res, 1999. 253(1): p. 210-29.
49. Six, I., et al., Akt signaling mediates VEGF/VPF vascular permeability in vivo. FEBS Lett, 2002. 532(1-2): p. 67-9.
50. Nicholson, K.M. and N.G. Anderson, The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal, 2002. 14(5): p. 381-95.
51. Wilhelm, S.M., et al., Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther, 2008. 7(10): p. 3129-40.
52. McCubrey, J.A., et al., Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta, 2007.
1773(8): p. 1263-84.
53. Krasilnikov, M.A., Phosphatidylinositol-3 kinase dependent pathways: the role in control of cell growth, survival, and malignant transformation. Biochemistry (Mosc), 2000. 65(1): p. 59-67.